IRulya Therapeutics (IRLA) Fireside Chat (FKA Orphai) - IRULYA THERAPEUTICS INC

Financial Performance:

• No specific revenue or earnings figures provided; Irulia Therapeutics is a pre-commercial clinical-stage biotech.
• Cash and cash equivalents are sufficient to fund operations through the end of 2028.
• Capital allocation is prioritized for advancing LAM-001 (inhaled rapamycin) through multiple Phase II milestones.

Guidance and Future Outlook:

• Phase II BOS Data: Expected top-line readout in Q1 2027 for the investigator-sponsored study led by UCSF.
• Phase IIb PHILD Data: Anticipated readout in Q1 2029.
• Phase II SAPH Data: Anticipated readout in Q4 2028.
• Patient Population Growth: Lung transplant numbers are rising (approaching 3,000–4,000 annually in the US), projecting the BOS patient pool to reach nearly 30,000 across the US and Europe by the early 2030s.
• Study Powering: Phase IIb PHILD (N=75) is powered at 80% to detect a 20% difference in PVR between arms.

Business Segments and Product Lines:

• Core Asset: LAM-001, a proprietary inhaled dry powder formulation of rapamycin (mTOR inhibitor).
• Indications:
  • PHILD (Pulmonary Hypertension associated with Interstitial Lung Disease): Phase II basket study (Phase IIa) showed significant improvements in Pulmonary Vascular Resistance (PVR), FVC, DLCO, 6-minute walk distance, and functional class. Current focus is a confirmatory Phase IIb trial.
  • BOS (Bronchiolitis Obliterans Syndrome): Irreversible fibrosis post-lung transplant with median survival of 2.5 years; currently no approved therapies.
  • SAPH (Sarcoidosis-Associated Pulmonary Hypertension): Next logical indication; affects ~15% of 200,000 US sarcoidosis patients; drug targets both PH and potential granuloma reduction.
• New Data: Phase IIa PHILD results demonstrated efficacy on dual compartments (vascular and parenchymal) despite patients being on triple background therapy.

Market and Competitive Landscape:

• Differentiation: LAM-001 bypasses first-pass liver metabolism and efflux proteins associated with oral rapamycin, allowing a 100-microgram dose (1/20th of oral dose) with minimal systemic toxicity and cough.
• Competition: No approved treatments exist for BOS; PHILD market is competitive (e.g., Provent, Riociguat, Bosentan history) but LAM-001 targets an unaddressed mTOR pathway.
• Adjacency: Management views Roivant's upcoming Phase 3 drug as complementary rather than competitive, believing LAM-001 can be used in conjunction with other agents.

Risks and Challenges:

• Clinical Risk: Oral rapamycin has historically shown prohibitive systemic toxicities; the success of the inhaled route is critical.
• Study Design: The Phase II BOS study is small (N=19) and investigator-sponsored; statistical significance is not expected, but a 5–10% delta in FEV1 is the target for pivotal advancement.
• Disease Nature: BOS is an irreversible fibroproliferative disease; reversal is unlikely, making stabilization the primary goal.
• Patient Progression: High attrition rates in the transplant population due to mortality from BOS.

Management Commentary and Tone:

• Tone: Highly confident and optimistic regarding the unique mechanism of action and clinical signals observed.
• Vision: Emphasizes "Unlocking Life-Extending Years of Airflow" to address fatal lung diseases with limited options.
• Strategy: Focus on proving efficacy in the most underserved, high-mortality indications (BOS, SAPH) where no treatments exist.
• Regulatory: Plan to include a placebo arm and dose-ranging (100mcg vs 200mcg) in Phase IIb to satisfy standard regulatory requirements.

Analyst Questions and Answers:

• Q: Impact of Roivant's Phase 3 drug on the market? A: Management believes it is complementary; LAM-001 targets a distinct mTOR mechanism and can be used with background therapies including new agents.
• Q: Drivers of increasing lung transplant rates? A: Combination of perfusion devices, use of marginal organs, and expanded transplant centers.
• Q: Significance of FEV1 decline in BOS? A: Every 1% decline correlates with a 3.4% increase in mortality; a 5–10% improvement in the drug arm vs placebo is the target for clinical meaningfulness.
• Q: Cash runway details? A: Funds operations through end of 2028, covering data readouts for BOS (2027), PHILD (2029), and SAPH (2028).

Other Key Points:

• Drug Name: Rebranded to "Irulia" (I-R-U-L-Y-A) to reflect "Inhaled Rapamycin" and the mission "Unlocking Life-Extending Years of Airflow."
• Precedent Data: Retrospective studies (2005, 2024) show oral mTOR inhibitors stabilize FEV1 in BOS, supporting the mechanistic hypothesis.
• Dual Action: The drug targets both the vascular compartment (PVR) and the parenchymal compartment (fibrosis/FEV1) in PHILD.
• Sarcoidosis Mechanism: Granulomas in sarcoidosis are mTOR-driven; oral cases show lesion clearance, suggesting potential for inhaled LAM-001 to address the underlying pathology.